BUSINESS
DCGI led panel formed to frame new New Drugs, Cosmetics and Medical Devices Bill starts process
"The committee has decided to conduct a consultative meeting with the Consumer Associations scheduled to held on September 19 between 2 - 4 pm," the notification released by Somani said.
BUSINESS
No new side effects found in COVID-19 antiviral Favipiravir: Glenmark
Glenmark said the time for fever resolution was four days while time for clinical cure was seven days.
BUSINESS
Poonawalla-backed Wellness Forever to file for Rs 1,600-crore IPO
The retail pharmacy chain will file its draft documents by end-September.
BUSINESS
Laurus Labs joins hands with Unitaid, CHAI to develop and commercialise pediatric HIV drug combo
Laurus will be provided with a financial incentive for a portion of their development and commercialisation costs. CHAI will work closely with Laurus Labs to provide technical and regulatory support to enable accelerated generic development and regulatory submission of the medication.
BUSINESS
IPO-bound PharmEasy parent appoints five independent directors, to hire over 200 engineers
“The fresh appointments bring a great amount of cognitive diversity to the board, with luminaries from the world of public service, technology, pharma, medical fraternity, and the consumer sector," the company said in a statement.
BUSINESS
Advanced Enzymes says its enzymes, probiotics aid faster recovery in long-COVID patients
The products were launched on Amazon under brand names ‘ImmunoSEB’ and ‘Biome ULTRA’ in the US and Indian markets.
BUSINESS
NABL a voluntary accreditation body, has no regulatory powers: N Venkateswaran, CEO
"Checking of compliance to the regulatory requirements falls under the purview of the respective applicable regulator," Venkateswaran says. NABL has been drawing flak, especially for issuing accreditation for labs that are not complying with regulatory practices.
BUSINESS
Indian pharmaceutical market grow at 17.7% in August
India’s $1.8 trillion pharmaceuticals market is showing signs of returning to normalcy as sales of Non-COVID products, which account for 63 percent of the market, is rising strongly while growth of some pandemic-related products like vitamins has tapered.
BUSINESS
Govt forms panel headed by DCGI to frame new Drugs, Cosmetics, Medical Devices bill
“The committee shall undertake pre legislative consultations and examine the present Act, previously framed Drugs and Cosmetics Bills and submit a draft document for a de-novo Drugs, Cosmetics and Medical Devices bill,” the notification said.
BUSINESS
Cipla seeks price hike for certain respiratory medications, writes to NPPA
Cipla spokesperson confirmed the development, and said the products impacted are a "small subset" of the overall basket of respiratory products.
BUSINESS
Panacea Biotec rolls out first batch of Sputnik V second jab
The second jab of Sputnik V is being manufactured at the Panacea Biotec’s facility in Himachal Pradesh
BUSINESS
Goldman Sachs-backed Aragen Life Sciences on expansion mode, evaluating select acquisition opportunities
With revenue of Rs 1,200 crore in the financial year 2021, Aragen provides outsourcing services for drug discovery, clinical trials, and manufacturing to over 450 clients globally, including many large biotech and pharmaceutical companies.
BUSINESS
Hetero to launch Tocilizumab, gets DCGI’s emergency use nod
While Hetero didn't announce the price of the drug, but the biosimilar version is expected to be cheaper than the branded Tocilizumab which is priced at Rs 40,600 per single injection. A COVID-19 patient would typically require about two injections.
BUSINESS
Govt utilised 23.6% of budgeted Rs 35,000 crore for COVID-19 vaccines till July
The government has spent Rs 9,229.31 crore between March and July to procure 124 crore doses from three manufacturers.
BUSINESS
SII puts Indian demand for COVID-19 vaccine above exports
"Once the supply-demand situation eases in India, we will think about exports," said one of the people, requesting anonymity.
BUSINESS
New list of essential medicines: 39 new drugs added, 16 dropped
Most of the new drugs added to the list were anti-cancer like Azacitidine and Fludarabine antiretroviral such as Dolutegravir, Darunavir+Ritonavir, new generation TB medications such as Bedaquiline and Delamanid, anti-allergy Montelukast, anti diabetes drugs like Teneligliptin and Insulin Glargine.
BUSINESS
Exclusive | SII, Bharat Biotech made additional 40-50 million doses of COVID-19 vaccine available in August
Increased vaccine supplies have helped the government to accelerate its inoculation drive
BUSINESS
Here is how Bombay Hemp Company is trying to create business out of Cannabis
Bombay Hemp Company or BOHECO was founded with a plan to create a vertically integrated company that produces hemp to make textiles, building materials, Ayurvedic remedies, and health and wellness products.
BUSINESS
Veeda Clinical Research filing for Rs 500 crore - Rs 700 crore IPO, sources say
The company sees increased traction in its core segment of studies of evaluating the generic versions of proprietary drugs that go off patent, as well bright prospects from clinical trials of biosimilars and novel drugs.
BUSINESS
Bharat Biotech on target to reach a billion doses, rolls out Covaxin from Ankleshwar unit
With specialised bio safety containment facilities in Hyderabad, Malur, Ankleshwar, and Pune, Bharat Biotech said it is steadily moving towards its aim of ~ 1 billion doses of annualised capacity.
BUSINESS
IPO-bound Ami Organics confident of growing business despite Chinese competition
The company has been able to gain significant market share on select intermediates over the years despite tough competition from Chinese suppliers, that dominate intermediate and APIs globally.
BUSINESS
IPO-bound Vijaya Diagnostic looks to deepen presence in AP, Telangana and East India
Vijaya Diagnostic will be the second IPO of a diagnostic lab chain to hit the market in less than a month. Earlier this month Krsnaa Diagnostics IPO was subscribed 64.40 times. The price band of the offer has been fixed at Rs 522 to Rs 531 per equity share.
BUSINESS
Cipla partners Kemwell to foray into respiratory biosimilars space
Cipla’s respiratory drug prowess combined with Kemwell’s expertise in biologics will accelerate bringing these essential products to market.
BUSINESS
J&J says COVID-19 booster jab generates strong antibody response
The interim data from new studies shows that a booster dose generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination, J&J has said
